Tripep AB (publ.) Interim Report, January - September 2005

• The loss after tax was SEK -16.3 million (-19.2 m). • Research and development costs were SEK 7.1 million (9.5 m), with an additional SEK 9.2 million capitalised in the first nine months of 2005. • As yet, the company has no operating income, and thus, had no net sales in the period. • Earnings per share were SEK -0.93 (-1.39). • The Board of Directors consummated a new issue with preferential rights for shareholders, pursuant to EGM approval. The issue was heavily over-subscribed, raising SEK 28 million for the company before issue costs. • Series F and G warrants were listed on the Stockholm Stock Exchange on 29 August 2005. • The clinical phase I/II trial of alphaHGA on HIV-positive individuals in Thailand began after the regulatory authorities granted approval. Preliminary results are expected to be available at the end of first quarter of 2006. For more information, please contact Jan Nilsson, Chief Executive Officer Tel: +46 (0)8 449 84 82, mobile: +46 (0)70 466 31 63 e-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research Tel: +46 (0)8 5858 1313, mobile: +46 (0)70 928 05 28 e-mail: anders.vahlne@ki.se

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.

Subscribe

Documents & Links